Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
429.00    -9.00 (-2.05%)
Bid:
427.40
Ask:
427.80
Spread: 0.40 (0.094%)
Market Cap: £2.21b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

Total Voting Rights

30 Jun 2025 16:00

RNS Number : 0389P
QinetiQ Group plc
30 June 2025
 

QinetiQ Group plc

Total Voting Rights

 

30 June 2025 - In accordance with the Financial Conduct Authority's (FCA) Disclosure Guidance and Transparency Rule 5.6.1R, QinetiQ Group plc ("the Company") notifies the market that as of 30 June 2025 the Company's issued ordinary share capital consists of 544,327,145 ordinary shares of one penny each. There are no shares held in treasury. 

Therefore, the total number of voting rights in the Company is 544,327,145. This figure may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

About QinetiQ:

QinetiQ is an integrated global defence and security company focused on mission-led innovation. QinetiQ employs circa 8,500 highly-skilled people, committed to creating new ways of protecting what matters most; testing technologies, systems, and processes to make sure they meet operational needs; and enabling customers to deploy new and enhanced capabilities with the assurance they will deliver the performance required.

 

For further information, please contact:

Stephen Lamacraft, Interim Group Investor Relations Director:

+44 (0) 7920 545841

Stephanie Mann, Group Head of Media Relations:

+44 (0) 7770 720268

James Field, Company Secretary:

+44 (0) 7841 662957

 

QinetiQ Group plc LEI: 213800S8OBDOZMCMUW34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBSGDLBXXDGUG
Date   Source Headline
9th Aug 20227:00 amRNSDelivering growth in the US with $45m contract win
5th Aug 20226:22 pmRNSProposed Acquisition of Avantus Federal LLC
1st Aug 20223:19 pmRNSHolding(s) in Company
21st Jul 20223:18 pmRNSResult of AGM
21st Jul 20227:00 amRNSFirst Quarter Trading Update
19th Jul 20225:24 pmRNSHolding(s) in Company
12th Jul 20222:09 pmRNSHolding(s) in Company
12th Jul 20221:47 pmRNSDirector/PDMR Shareholding
29th Jun 20225:09 pmRNSDirector/PDMR Shareholding
27th Jun 202212:35 pmRNSHolding(s) in Company
15th Jun 20229:53 amRNSHolding(s) in Company
13th Jun 202212:59 pmRNSDirector/PDMR Shareholding
13th Jun 202212:28 pmRNSAnnual Financial Report
6th Jun 202210:52 amRNSHolding(s) in Company
30th May 202212:03 pmRNSNotification of Major Shareholding
23rd May 20227:00 amRNSConfirmation of Full Year Results
19th May 20227:00 amRNSPreliminary Results
18th May 20227:00 amRNSDirectorate Change
17th May 202211:24 amRNSHolding(s) in Company
16th May 20221:45 pmRNSHolding(s) in Company
10th May 202211:49 amRNSDirector/PDMR Shareholding
27th Apr 20227:00 amRNSInvestor Seminar: Delivering our global ambition
26th Apr 20221:37 pmRNSHolding(s) in Company
21st Apr 20229:15 amRNSHolding(s) in Company
20th Apr 20227:00 amRNSFourth Quarter Trading Update
12th Apr 202212:45 pmRNSDirector/PDMR Shareholding
10th Mar 202211:27 amRNSDirector/PDMR Shareholding
10th Feb 202211:52 amRNSDirector/PDMR Shareholding
10th Feb 202211:52 amRNSDirector/PDMR Shareholding
2nd Feb 20228:42 amRNSHolding(s) in Company
24th Jan 202211:12 amRNSDirector/PDMR Shareholding
19th Jan 20221:43 pmRNSHolding(s) in Company
18th Jan 20227:00 amRNSThird Quarter Trading Update
17th Jan 20227:00 amRNSAppointment of President and CEO of QinetiQ US
11th Jan 202211:43 amRNSDirector/PDMR Shareholding
5th Jan 20225:05 pmRNSDirector/PDMR Shareholding
20th Dec 20219:21 amRNSDirector Declaration
10th Dec 202112:42 pmRNSDirector/PDMR Shareholding
6th Dec 202112:16 pmRNSHolding(s) in Company
18th Nov 202111:04 amRNSDirector/PDMR Shareholding
17th Nov 202110:54 amRNSDirector/PDMR Shareholding
16th Nov 202111:24 amRNSDirector/PDMR Shareholding
11th Nov 20217:00 amRNSInterim Results
10th Nov 202112:12 pmRNSDirector/PDMR Shareholding
1st Nov 202111:43 amRNSBlock listing Interim Review
19th Oct 20219:16 amRNSHolding(s) in Company
14th Oct 20217:00 amRNSTrading Update
12th Oct 202110:43 amRNSDirector/PDMR Shareholding
10th Sep 20212:07 pmRNSDirector/PDMR Shareholding
31st Aug 20212:35 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.